Advertisement

Drugs & Therapy Perspectives

, Volume 29, Issue 11, pp 336–341 | Cite as

Buprenorphine/naloxone sublingual tablet (Zubsolv®): a guide to its use in the maintenance treatment of opioid dependence in the USA

  • Katherine A. Lyseng-WilliamsonEmail author
Adis Drug Clinical Q&A

Abstract

Zubsolv® is a new sublingual formulation of buprenorphine/naloxone that is indicated for the maintenance treatment of opioid dependence in the USA. The effectiveness and tolerability of buprenorphine/naloxone in this indication is well established. Relative to other sublingual formulations of buprenorphine/naloxone, Zubsolv® dissolves more rapidly, has greater bioavailability, tastes better, and may be preferred by many patients.

Keywords

Naloxone Buprenorphine Atazanavir Opioid Dependence Opioid Withdrawal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgement

The manuscript was reviewed by: S. Helm, Pacific Coast Pain Management Center, Laguna Hills, CA, USA; M. Hillhouse, UCLA Integrated Substance Abuse Programs, Los Angeles, CA, USA, C.M. Renzelli, Gateway Rehabilitation Center, Moon Township, PA, USA.

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

References

  1. 1.
    Colson J, Helm S, Silverman SM. Office-based opioid dependence treatment. Pain Physician. 2012;15(3 Suppl):ES231–6.Google Scholar
  2. 2.
    Holmes D. Prescription drug addiction: the treatment challenge. Lancet. 2012;379(9810):17–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med. 2011;5(4):254–63.PubMedCrossRefGoogle Scholar
  4. 4.
    Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines. J Manag Care Pharm. 2010;16(1 Suppl B):S14–21.Google Scholar
  5. 5.
    Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs. 2006;20(9):697–712.PubMedCrossRefGoogle Scholar
  6. 6.
    Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209.Google Scholar
  7. 7.
    Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008(2):CD002207.Google Scholar
  8. 8.
    Mégarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev. 2006;25(2):79–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978;35(4):501–16.PubMedCrossRefGoogle Scholar
  10. 10.
    Bickel WK, Stitzer ML, Bigelow GE, et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther. 1988;247(1):47–53.PubMedGoogle Scholar
  11. 11.
    Walsh SL, June HL, Schuh KJ, et al. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl). 1995;119(3):268–76.PubMedCrossRefGoogle Scholar
  12. 12.
    Wesson DR. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S. J Psychoactive Drugs. 2004;Suppl. 2:119–28.Google Scholar
  13. 13.
    Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Ciraulo DA, Hitzemann RJ, Somoza E, et al. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J Clin Pharmacol. 2006;46:179–92.PubMedCrossRefGoogle Scholar
  15. 15.
    Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis. 2006;43(Suppl 4):S173–7.Google Scholar
  16. 16.
    Naloxone hydrochloride injection: US prescribing information. Lake Forest (IL): Hospira, Inc. 2007.Google Scholar
  17. 17.
    Zubsolv® (buprenorphine and naloxone sublingual tablets) for sublingual administration (CIII): US prescribing information. New York: Orexo US, Inc. 2013.Google Scholar
  18. 18.
    Donaher PA, Welsh C. Managing opioid addiction with buprenorphine. Am Fam Physician. 2006;73(9):1573–8.PubMedGoogle Scholar
  19. 19.
    Jönsson M, Fischer A, Tiberg C, et al. A novel buprenorphine/naloxone tablet formulation for the treatment of opioid dependence [poster]. In: 44th Annual Medical-Scientific Conference of the American Society of Addiction Medicine; 25–28 Apr 2013; Chicago.Google Scholar
  20. 20.
    Ling W, Hillhouse M, Domier C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction. 2009;104(2):256–65.PubMedCrossRefGoogle Scholar
  21. 21.
    Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs. 2009;69(5):577–607.PubMedCrossRefGoogle Scholar
  22. 22.
    Ling W, Jacobs P, Hillhouse M, et al. From research to the real world: buprenorphine in the decade of the Clinical Trials Network. J Subst Abuse Treat. 2010;38(Suppl 1):S53–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Orexo. Orexo takes large step forward on the road to improve treatment for people dependent on opioid pain killers [media release]. 2012 Jul 2 [online]. Available from: http://www.orexo.com/en/Investor-Relations/Press-releases/?guid=680249.
  24. 24.
    Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–58.PubMedCrossRefGoogle Scholar
  25. 25.
    Kamien JB, Branstetter SA, Amass LA. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid dependent patients. Heroin Addict Relat Clin Probl. 2008;10(4):5–18.Google Scholar
  26. 26.
    Kakko J, Grönbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry. 2007;164(5):797–803.PubMedCrossRefGoogle Scholar
  27. 27.
    Apelt SM, Scherbaum N, Gölz J, et al. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care. Pharmacopsychiatry. 2013;46(3):94–107.PubMedCrossRefGoogle Scholar
  28. 28.
    Stimolo C, Favero VD, Zecchinato G, et al. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre. Clin Drug Investig. 2010;30(Suppl 1):27–31.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations